Significant progress has been made in the development of a new generation of monoclonal antibodies against the infection of "super drug-resistant bacteria". On July 18, 2018, Mabwell (Shanghai) Bioscience Co., Ltd. and Tongji University signed a technology transfer agreement. Based on the research and development achievements of Medical College of Tongji University, the two sides will cooperate in the development of anti-infective monoclonal antibody drugs with independent intellectual property rights. After industrialization of this achievement, it will provide more effective drugs for the clinical treatment of "super-resistant bacteria" infection, and fill the blank in the research and development of antibody drugs in this field in China.

The transfer of scientific research results come from the Anti-infective Drug Research Laboratory, Medical College, Tongji University, by Professor An Maomao’s research and development team to complete, but are also the achievement from multi-disciplinary joint efforts. The humanized monoclonal antibody targeting drug was developed based on the important virulence factors of human tissues infected and damaged by super-resistant bacteria. At present, there is no similar product on the market both in the domestic and overseas. The results for the drug will be used in clinical prevention and treatment of invasive fungal infections more effectively, by assisting the immune system to faster remove fungi in vivo, shorten the course of anti-infection treatment, reduce the number of doses, so as to benefit clinical patients.

With the long-term use and even abuse of antimicrobial drugs, some bacterial susceptibility to antimicrobial drugs gradually declined, drug-resistant strains continue to emerge, and even the emergence of all antimicrobial drug-resistant "super-resistant bacteria". In recent years, "super drug-resistant bacteria" has appeared in many countries and regions around the world. At present, "super-resistant bacteria" infection is common in hospitals, especially in intensive care unit (ICU). Last year, the World Health Organization published its first list of "key pathogens" for antibiotic resistance, calling for research and development of new antibiotic-resistant drugs.

With the long-term use and even abuse of antimicrobial drugs, some bacterial susceptibility to antimicrobial drugs gradually declined, drug-resistant strains continue to emerge, and even the emergence of "super-resistant bacteria"  resistant to all antimicrobial drugs. In recent years, "super drug-resistant bacteria" has appeared in many countries and regions around the world. At present, "super drug-resistant bacteria" infection is really common in hospitals, especially in intensive care unit (ICU). Last year, the World Health Organization published its first list of "key pathogens" for antibiotic resistance, calling for research and development of new antibiotic-resistant drugs.

In order to facilitate the industrialization of medical research results from colleges and universities, and benefit clinical patients as soon as possible, Mabwell (Shanghai) and Tongji University will work together to promote the technology to the industrial stage. The transfer of research outputs is based on the cooperation and development under the Framework Cooperation Agreement on Anti-infective Drugs signed by the two sides last year. The two sides have cooperated closely since the beginning of the project. In the course of the research, complementary advantages, honest communication and frequent interaction have greatly accelerated the R&D projects and created a new mode of cooperation between enterprises and universities.

News source: network of WEN WEI PO

Source address: http://www.whb.cn/zhuzhan/xue/20180724/205375.html